Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors

The development of immunotherapy agents has revolutionized the field of oncology. The only FDA-approved immunotherapeutic approach in breast cancer consists of immune checkpoint inhibitors, yet several novel immune-modulatory strategies are being actively studied and appear promising. Innovative imm...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdou, Yara, Goudarzi, Atta, Yu, Jia Xin, Upadhaya, Samik, Vincent, Benjamin, Carey, Lisa A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9646259/
https://www.ncbi.nlm.nih.gov/pubmed/36351947
http://dx.doi.org/10.1038/s41523-022-00486-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9646259/
https://www.ncbi.nlm.nih.gov/pubmed/36351947
http://dx.doi.org/10.1038/s41523-022-00486-y

Ejemplares similares